Comparison of the Alzheimer's disease assessment scale cognitive subscale and the vascular dementia assessment scale in differentiating elderly individuals with different degrees of white matter changes: The ladis study

Dementia and Geriatric Cognitive Disorders

Volumn 24, Issue 2, 2007, Pages 73-81

  Ylikoski, Raija ^a   Jokinen, Hanna ^a   Andersen, Pia ^a   Salonen, Oili ^b   Madureira, Sofia ^c   Ferro, Jose ^c   Barkhof, Frederik ^d   Van Der Flier, Wiesje ^e   Schmidt, Reinhold ^f   Fazekas, Franz ^f   Scheltens, Philip ^e   Waldemar, Gunhild ^g   Salvadori, Emilia ^h   Pantoni, Leonardo ^h   Inzitari, Domenico ^h   Erkinjuntti, Timo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Centro de Estudos Egas Moniz   (Portugal)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g Mental Health Services CPH   (Denmark)

^h UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cognition; Neuropsychology; Vascular Dementia Assessment Scale cognitive subscale; White matter changes

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; GERIATRICS; HUMAN; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; VASCULAR DEMENTIA ASSESSMENT SCALE; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; DEMENTIA, VASCULAR; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOARAIOSIS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL RECALL; NEUROPSYCHOLOGICAL TESTS; PROBLEM SOLVING; PROSPECTIVE STUDIES; PSYCHOMETRICS; REACTION TIME; REPRODUCIBILITY OF RESULTS; RETENTION (PSYCHOLOGY); STATISTICS; VERBAL LEARNING;

EID: 34447629327     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103865     Document Type: Article

References (41)

1. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
2. Doraiswamy PM, Kaiser L, Bieber F, Garman RL: The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-183.
3. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al: A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
4. Youn JC, Lee DY, Kim KW, Lee JH, Jhoo JH, Lee KU, Ha J, Woo JI: Development of the Korean version of Alzheimer's Disease Assessment Scale (ADAS-K). Int J Geriatr Psychiatry 2002;17:797-803.
5. Farlow MR, Lane R, Kudaravalli S, He Y: Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers. Pharmacogenomics J 2004;4:332-335.
6. Kemp PM, Holmes C, Hoffman S, Wilkinson S, Zivanovic M, Thom J, Bolt L, Fleming J, Wilkinson DG: A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1567-1570.
7. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y: Long-term outcomes of galantamine treatment in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2004;12:473-482.
8. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
9. Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius H-J, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebocontrolled trial (MMM300). Stroke 2002;33:1834-1839.
10. Pratt RD, Perdomo CA; the Donepezil VaD 307 and 308 Study Groups: Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann NY Acad Sci 2002;977:513-522.
11. Wilcock G, Möbius HJ, Stöffler A;on behalf of the MMM 500 Group: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002;17:297-305.
12. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; the Donepezil 308 Study Group: Donpezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003;61:479-486.
13. Erkinjuntti T, Kurz A, Small GW, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
14. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV: An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765-1782.
15. Lilienfeld S, Kurz A: Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine. Ann NY Acad Sci 2002;977:487-492.
16. Small G, Erkinjuntti T, Kurz A, Lilienfeld S: Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascluar disease. CNS Drugs 2003;17:905-914.
17. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal L: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997;11:S13-S21.
18. Salloway S, Ferris S, Kluger A, Goldma R, Grising T, Kumar D, Richardson S: Efficacy of donepezil in mild cognitive impairment. A randomized placebo-controlled tiral. Neurology 2004;63:651-657.
19. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowier JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky S: Vascular cognitive impairment. Lancet Neurol 2003;2:89-98.
20. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.
21. Wen HM, Mok VCT, Fan YH, Lam WWM, Tang W, Wong A, Huang RX, Wong KS: Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 2004;3:1826-1830.
22. Van der Flier WM, van Straaten ECW, Barkhof F, Verdelho A, Madureira S, Pantoni L, Inzitari D, Erkinjuntti T, Crisby M, Waldemar G, Schmidt R, Fazekas F, Scheltens P: Small vessel disease and general cognitive function in nondisabled elderly: the LADIS Study. Stroke 2005;36:2116-2120.
23. DeCarli C, Murphy DG, Tranh M, Grady CL, Haxby JV, Gillette JA, Salerno JA, Gonzales-Aviles A, Horwitz B, Rapoport SI, et al: The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-2084.
24. Jokinen H, Kalska H, MäntyläR, Pohjasvaara T, Ylikoski R, Hietanen M, Salonen O, Kaste M, Erkinjuntti T: Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006;77:28-33.
25. Price CC, Jefferson AL, Merino JG, Heliman KM, Libon DJ: Subcortical vascular dementia. Integrating neuropsychological and neuroradiologic data. Neurology 2005;65:376-382.
26. Ylikoski R, Ylikoski A, Erkinjuntti T, et al: White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 1993;50:818-824.
27. Ferris SH: Cognitive outcome measures. Alzheimer Dis Assoc Disord 1999;13:S140-S142.
28. Ferris SH: General measures of cognition. Int Psychogeriatr 2003;15:215-217.
29. Pantoni L, Basile AM, Pracucci G, Asplund K, Bogouslavsky J, Chabria H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, O'Brien J, Scheltens P, Visser MC, Wahlund L-O, Waldemar G, Wallin A, Inzitari D: Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005;24:51-62.
30. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
31. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
32. Madureira S, Verdelho A, Ferro J, Basile AM, Chabriat H, Erkinjuntti T, Fazekas F, Hennerici M, O'Brien J, Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund L-O, Waldemar G, Wallin A, Inzitari D; on behalf of the LADIS Study Group:Development of a neuropsychological battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): experience and baseline data. Neuroepidemiology 2006;27:101-116.
33. Cronbach LJ: Essentials of Psychological Testing, ed 4. New York, Harper & Row Publishers, Inc, 1984.
34. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's disease and normal aging. Am J Neuroradiol 1987;149:351-356.
35. Van Straaten ECW, Fazekas F, Rostrup E, Scheltens P, Schmidt R, Pantoni L, Inzitari D, Waldemar G, Erkinuntti T, Mäntylä R, Wahlund L-O, Barkhof F: Impact of white matter hyperintensities scoring method on correlations with clinical data. The LADIS Study. Stroke 2006;37:836-840.
36. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC: Impact of APOE in mild cognitive impairment. Neurology 2004;63:1898-1901.
37. Sahcdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JCL, Wen W, Zagami AS: The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004;62:912-919.
38. Perret E: The left frontal lobe in man and the suppression of habitual responses in verbal categorical behavior. Neuropsychologia 1974;12:323-330.
39. Fontaine A, Azouvi P, Remy P, Bussel B, Samson Y: Functional anatomy of neuropsychological deficits after severe traumatic brain injury. Neurology 1999;53:1963-1968.
40. Lezak MD: Neuropsychological Assessment. New York, Oxford University Press, 1995.
41. Burgess PW: Theory and methodology in executive function and research; in Rabbit P (ed): Methodology of Frontal and Executive Functions. East Sussex, Psychological Press, 1997, pp 81-116.